



The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

OPEN ACCESS

Edited by:

Issy Laher, University of British Columbia, Canada

Reviewed by:

Lei Shen, Wuhan University, China Samy Cadranel, Queen Fabiola Children's University Hospital, Belgium

*Correspondence:

Ping Yi pyi219@163.com

⁺These authors have contributed equally to this work

Specialty section:

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: 18 June 2019 Accepted: 26 December 2019 Published: 04 February 2020

Citation:

Hu Q, Peng Z, Li L, Zou X, Xu L, Gong J and Yi P (2020) The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front. Pharmacol. 10:1694. doi: 10.3389/fphar.2019.01694

Qian Hu^{1†}, Ze Peng^{1†}, Lingli Li¹, Xin Zou¹, Lijun Xu¹, Jing Gong² and Ping Yi^{2*}

¹ Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ² Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Berberine-containing quadruple therapy (adding berberine to the standard triple therapy) is being used to treat *Helicobacter pylori* infection, but the effects in randomized controlled trials (RCTs) are still controversial. Therefore, a meta-analysis is needed to estimate the efficacy and safety of berberine-containing quadruple therapy on *Helicobacter pylori* eradication.

Methods: Ten databases were searched to find the available literature. RCTs about the efficacy and safety of berberine-containing quadruple therapy on *Helicobacter pylori* eradication were included. The data of *Helicobacter pylori* eradication rate, peptic ulcer healing rate, relieving rate of clinical symptoms and adverse events were extracted to appraise the net change with a fixed or randomized effect model.

Results: A total of 13 articles were included in the analysis. Pooled results showed that the addition of berberine in standard triple therapy significantly improved *Helicobacter pylori* eradication rate (RR 1.22; 95% Cl 1.16 to 1.27; $l^2 = 12\%$), increased the peptic ulcer healing rate (RR 1.15; 95% Cl 1.10 to 1.19; $l^2 = 44\%$), relieved the clinical symptoms (RR 1.11; 95% Cl 1.06 to 1.17; $l^2 = 44\%$) and reduced the incidence of side events (RR 0.65; 95% Cl 0.53 to 0.80; $l^2 = 58\%$) comparing to the standard triple therapy.

Conclusions: The analysis showed that the addition of berberine in standard triple therapy could improve *Helicobacter pylori* eradication rate and clinical symptom remission rate, accelerate ulcer healing, and reduce adverse events, which is very beneficial to clinical work in China.

Keywords: berberine, Helicobacter pylori, standard triple therapy, eradication rate, systematic review

INTRODUCTION

Helicobacter pylori (H. pylori) infection is highly prevalent worldwide. In Northern Europe and North America, approximately one-third of adults are infected. Worse still, in South and East Europe, South America, and Asia, the prevalence of H. pylori is higher than 50% (Eusebi and Zagari, 2014; Xu et al., 2014). H. pylori infection is highly associated with the occurrence of gastrointestinal diseases, including gastric inflammation, peptic ulcers, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma (Yang and Lu, 2014; Debraekeleer, 2018). In China, the infection rate of H. pylori is 40%-60% (Chen et al., 2019). In recent years, in addition to its role in gastrointestinal diseases, several nongastric issues have been found to have a close relationship with H. pylori infection (Adachi et al., 2018; Yong and Upala, 2018; Lee et al., 2018). H. pylori treatment relies on a combination of antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, and antisecretory agents, such as proton pump inhibitors (PPIs) (Yang and Lu, 2014). A standard triple therapy consisting of a PPI and two antibiotics (clarithromycin and amoxicillin) has been widely used in China since 2011. With the resistance of *H. pylori* to antibiotics increasing, the efficacy of triple therapy is declining. Bismuth-containing quadruple therapy was proposed in China in 2012 (Liu et al., 2012). Unfortunately, a questionnaire survey among digestive doctors in 100 hospitals across the country showed that the application rate of bismuth-containing quadruple therapy was only 33% in China until 2017 (Xie and Lv, 2017). What's the reason? Adding bismuth to triple therapy reduced the compliance of patients because of its high frequency of adverse events, such as vomiting, abdominal pain, black tongue, and diarrhea (Graham and Lee, 2015; Kahramanoğlu et al., 2017). More importantly, bismuth has been substituted by berberine, a traditional Chinese medicine (TCM), for the eradication of H. pylori in China.

Berberine is a kind of isoquinoline alkaloid isolated from TCM Rhizoma coptidis and cypress. As an "Eastern antibiotic" in TCM, berberine has been used to treat diarrhea for a thousand years (Zhang, 1992). Recently, many experiments have proved that berberine has anti-H. pylori ability in vivo and in vitro (Huang et al., 2015; Wu et al., 2018). Berberine can effectively suppress multiresistant strains of *H. pylori*, and the minimum *H*. pylori inhibitory concentration of amoxicillin and tetracycline was lowered after the berberine intervention in vitro (Huang et al., 2015). Berberine can also suppress the expression of proinflammatory genes and upregulate antiinflammatory gene expression in H. pylori-infected mice (Wu et al., 2018). With the efficacy of the standard triple therapy for *H. pylori* declining, the anti-H. pylori property of berberine has received more attention. In China, an increasing number of randomized controlled clinical trials confirmed the efficacy of berberine combined with standard triple therapy on H.pylori eradication. A recent open-label randomized phase IV trial showed that both berberine-containing quadruple therapy and bismuthcontaining quadruple therapy achieved the recommended efficacy and can be recommended as the first-line treatment for

H. pylori eradication in Xi'an, China (Zhang et al., 2017). Therefore, based on the extensive collection of literature, we designed this randomized controlled trial to assess the efficacy and safety of the addition of berberine in standard triple therapy on *H. pylori* eradication.

MATERIALS AND METHODS

Methods

We conducted and reported this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement protocol (Moher et al., 2015).

Search Strategy

To determine the effect of berberine on *H. pylori* eradication, PubMed, EMBASE, Web of Science, the Cochrane Library, the Chinese Biomedical Literature Database (CBM), the Wan Fang Medical Database, the China National Knowledge Internet (CNKI), the China Academic Journal Network Publishing Database (CAJD), the Chinese Science Citation Database (CSCD), and the China Science and Technology Journal Database (CSTJ) were searched. All the above databases were searched from the available date of inception until the latest issue (January 2018). No language restriction was used.

Search strategies were as follows: for English databases, we use text terms such as berberine and *Helicobacter pylori* or berberine and *H. pylori*; for Chinese databases, we use text terms such as "Huang Lian Su" or "Xiao Bo Jian" and "You Men Luo Xuan Gan Jun" or "You Men Luo Gan Jun." Huang Lian Su and Xiao Bo Jian are the alternative names for berberine in Chinese; You Men Luo Xuan Gan Jun and You Men Luo Gan Jun are the alternative names of *H. pylori* in Chinese. A filter for clinical trials was applied. References were also searched to retrieve the related literature. Through reading the title and summary, the preliminary screening was completed. Then full texts of the applicable studies were downloaded and screened.

Selection Criteria

The inclusion criteria of randomized clinical trials (RCTs) were as follows. (1) Patients with *H. pylori* infections that were positive, preexisted or newly diagnosed (either urea breath test [UBT] or rapid urease test [RUT]) were included. (2) The standard triple therapy (two antibiotics and one PPI) was chosen as a control group; the berberine-containing quadruple therapy (adding berberine to the standard triple therapy) was chosen as the experimental group, which means that berberine added to the treatment group was the only treatment difference between the two groups. (3) The data of outcomes (*H. pylori* eradication rate, improvement of ulcers, relieving rate of clinical symptoms and adverse events) were countable.

The excluded criteria were as follows: (1) Case reports, reviews, animal or cell studies, and studies without a control group. (2) Berberine combined with other drugs served as a control group, or berberine was substituted for an antibiotic in the experiment group. (3) The control group did not adapt to the

standard triple therapy. (4) The data of outcomes were not accessible.

Data Extraction

Two reviewers (Qian Hu and Ze Peng) independently extracted the information. They extracted data concerning details of the author, publication year, diagnosis, diagnostic method, age, the number of participants, characteristics for both intervention and control group (treatment protocols, drug name), treatment duration, and outcomes. The primary outcomes consisted of *H. pylori* eradication rate, improvement of ulcers, relieving rate of clinical symptoms and adverse events. Where outcomes were ambiguous or missing in an article, the decision to retrieve from that article was resolved by consensus.

Methodological Quality

Jadad scores were used to assess the quality of each included study independently. The Jadad score is usually evaluated through three main parts as described below: the method of randomization (0–2 points), blind method (0–2 points), and description of withdrawals and dropouts (0–1 point). With a total score of five, studies with Jadad scores higher than 3 were regarded as high quality; otherwise, it was considered low quality. All of the included studies had a high Jadad score in this meta-analysis.

Data Synthesis and Analysis


Review Manager meta-analysis software 5.3 and Stata 12.0 software were used to summarize the effect of berberine. We

calculated the risk ratio (RR) and the 95% confidence interval (CI) for count data. The heterogeneity was evaluated with the chi square test, df test, Tau test, and the Higgins I² test. The heterogeneity test was conducted among the studies, with P < 0.05 being the test level. When P > 0.05, there was no significant heterogeneity among the studies, and the fixed-effect model was selected for analysis; otherwise, the random effect model was used for the combined analysis. The overall effect was tested by using the Z score with significance set at P < 0.05. Egger's tests were carried out using Stata 12.0 software to determine the publication biases.

RESULTS

Study Inclusions

As illustrated in **Figure 1**, 147 studies were retrieved from the databases. With the removal of duplicates, the titles and abstracts of 48 studies have remained. The remaining studies were further carefully searched, and seven studies were eliminated due to animal or cell experiments (n = 3) and nonrandomized clinical trials (n = 4). Then, 28 records were excluded because of no standard triple therapy (n = 10) in the control group or berberine as an alternative drug (n = 18) in the experiment group. Finally, 13 articles were included in our meta-analysis. (Ma et al., 2011; Chen et al., 2013; Dong and Dai., 2013; Lu et al., 2013; Qi and Xiao, 2013; Si and Hu, 2013; Zhou et al., 2013; Zhang GF, 2014; Zhang XX, 2014; Hu, 2015; Ma, 2016; Huang et al., 2017; Luo et al., 2017).



Characteristics of the Studies

Thirteen RCTs published as full text between 2011 and 2017 met our inclusion criteria. All RCTs originated from China and were published in Chinese. The details of the trials are listed in **Table 1**. Together, those trials included 2,111 patients. In the studies included, there were no significant differences in the general data (age, gender, duration of illness) between the control group and the experimental group. All subjects were positive for *H. pylori*. The control group received the standard triple therapy. Based on the standard triple therapy, berberine was added separately to the experiment group. The efficacy of adding berberine to triple therapy for *H. pylori* eradication was studied. Additionally, ten of them gave the outcomes about the healing of ulcers using a gastroscope, and five of them described the improvement of clinical symptoms after treatment. All studies recorded adverse reactions.

Two kinds of triple therapies were used in all the included studies: omeprazole, clarithromycin, and amoxicillin (n=7) and rabeprazole, clarithromycin, and amoxicillin (n = 6). Concerning treatment time, five articles were for 7 days, and eight articles were for 14 days. All experimental groups received additional oral berberine tablets three times a day. The dose of berberine varied in all included studies: 120 mg in six papers, 300 mg in four papers, 400 mg in one paper, and 500 mg in two papers. There are seven studies in which the dose of berberine was greater than or equal to 300 mg. At present, two methods were used to determine the Hp infection: the UBT and the RUT. In the

TABLE 1 | Characteristics of included trials (two-armed parallel group).

included literature, there are five studies using UBT as the criterion, six papers as the standard of RUT, and two papers combined both UBT and RUT. The correct detection time of Hp eradication is 28 days after treatment, eight cases stated 4 weeks after the end of treatment, and five cases did not mention the specific time.

Quality of Included Studies

Based on Jadad scores, all studies were deemed high quality. Eight studies scored three points, and the rest scored four points. These studies reported the randomized method, blind and withdrawal/dropout. The average score of 3.38 indicated the risk of bias (shown in **Supplementary Table 1**).

H. pylori Eradication Rate

Thirteen trials (involving 2,111 patients) evaluated the *H. pylori* eradication effect of berberine with the standard triple therapy versus the standard triple therapy. The heterogeneity result showed that the included studies had clinical and statistical homogeneity, so a fixed-effect model was chosen. As shown in **Figure 2A**, the berberine-containing group had a higher Hp eradication rate than the control group (RR 1.22; 95% CI 1.16 to 1.27; $I^2 = 12\%$). The results of the meta-regression showed that there was no difference regarding the publication year, the method, the PPI type, the total number of participants, the dose of berberine, and the time of treatment duration (shown in **Supplementary Figure 1**). The subgroup

| Author and year | Diagnosis | Number of patients | | Average Age or range | Intervention | Control | Duration | Outcome | Dose | Method (A or B) |
|-----------------------|------------------------|--------------------|---------|-------------------------|---------------------|-----------------|----------|----------------------|-------|--------------------|
| | | Experiment | control | - | | | | | | |
| Ma et al., 2011 | PU/CG | 54 | 42 | 40.94 ± 15.64 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 7d | Hp, PU, AE | 120mg | А |
| Si and Hu, 2013 | PU, Hp ⁺ | 45 | 45 | 43.5 ± 3.7 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PU, AE | 400mg | ΑB |
| Qi and Xiao, 2013 | Hp ⁺ | 210 | 210 | 44.2 ± 2.5 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 7d | Hp, AE | 300mg | A |
| Lu et al., 2013 | Hp ⁺ | 84 | 78 | 40.87 ± 14.64 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 7d | Hp, PU, AE | 120mg | A |
| Zhou et al., 2013 | Hp ⁺ , T2DM | 50 | 50 | 30–75 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PU, AE, FBG | 300mg | В |
| Chen et al., 2013 | Hp ⁺ | 140 | 125 | 55 ± 26 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, AE, CS | 300mg | A |
| Dong and Dai, 2013 | Hp+ | 50 | 50 | 39.8 ± 15.1 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 7d | Hp, PU, AE,CS | 120mg | В |
| Zhang, 2014 | Hp+ | 100 | 100 | 43.3 ± 14.4 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 14d | Hp, PU, AE | 120mg | В |
| Zhang, 2014 | PU | 50 | 50 | 43.5 ± 3.7 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PU, AE,CS | 500mg | В |
| Hu, 2015 | Hp ⁺ | 53 | 53 | 49.7 ± 10.6 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PU, AE | 500mg | A |
| Ma, 2016 | Hp ⁺ | 55 | 55 | 28–58 | RAB,AMO,CLA, BBR | RAB,AMO, CLA | 7d | Hp, AE, CS | 120mg | В |
| Huang et al., 2017 | PU, Hp ⁺ | 100 | 100 | 46.2 ± 11.0 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PU, AE | 300mg | ΑB |
| Luo et al., 2017 | Hp⁺, PU, T2DM | 81 | 81 | 27–57 | OME,AMO,CLA, BBR | OME,AMO, CLA | 14d | Hp, PUAE, FBG, CS | 120mg | В |

RAB, rabeprazole; OME, omeprazole; AMO, amoxicillin; CLA, clarithromycin; BBR, berberine; PU, peptic ulcer; CG, chronic gastritis; Hp⁺:helicobater pylori positive; AE, adverse events; CS, clinical symptom; T2DM, type 2 diabetes; FBG, fasting blood glucose; Dose, the dose of Berberine; Method, A-uera breath test; B-Rapid urease test.

analyses regarding the time of treatment duration suggested no significance (**Figure 2B**). In the subgroup concerning the dose of berberine, we combined 300, 400, and 500 mg into one group and grouping the dose as low dose (120 mg) and high dose (\geq 300 mg). The result indicated that there is no significant difference between low dose group and high dose group for the

efficiency of *H. pylori* eradication, but more trials needed to be performed (**Figure 2C**).

Peptic Ulcer Healing Rate

Ten trials (involving 1,198 patients) recorded conditions of the ulcer lesions after treatment. There was no clinically and




FIGURE 2 | The pooled effects of berberine-containing quadruple therapy on *H.pylori* eradication rate (A). Forest plot comparing berberine-containing quadruple treatment with the standard triple therapy; (B). Subgroup analysis about the treatment duration; (C). Subgroup analysis about the dose of berberine.

statistically significant heterogeneity in these trials. When red or white scars formed, ulcers completely healed, or ulcer lesions shrunk below 50%, and the treatment group was judged to be effective. As shown in **Figure 3A**, there were more effective cases in the berberine-containing group (577/609) than in the control group (486/589) (RR 1.15; 95% CI 1.10 to 1.19; $I^2 = 44\%$). The results of the meta-regression showed that there was no difference regarding the publication year, the method, the PPI type, the total number of participants, the dose of berberine, and the time of treatment duration (shown in **Supplementary Figure 2**). There was no significant change in sensitivity analyses. However, in the subgroup concerning the time of treatment duration, the result indicated a significant difference (**Figure 3B**).

Relieving Rate of Clinical Symptoms

As illustrated in **Figure 4**, five trials (involving 737 patients) described the improvement of clinical symptoms of berberinecontaining quadruple therapy. The included literature classified the improvement of clinical symptoms into complete remission, marked effect, effectivity, and inefficiency. Considering that meta-analysis only performs binary variable analysis on the count data (if valid and invalid), we combined the first three outcomes with the result of clinical improvement. The results showed that the clinical improvement of the treatment group was better than that of the control group (RR 1.11; 95% CI 1.06 to 1.17; $I^2 = 44\%$). The results of meta-regression showed that there were no differences regarding the PPI type, the dose of berberine, and the time of treatment duration. The subgroup analyses and sensitivity analysis demonstrated no significant change (shown in **Supplementary Figure 3**).

Adverse Effect

Thirteen trials (involving 2,111 patients) evaluated the adverse events in the berberine-containing group compared with the control group. Side events were mainly manifested as gastrointestinal reactions, such as nausea, vomiting, abdominal distension, diarrhea, and anorexia. Heterogeneity tests ($I^2 = 58\%$) suggested that there was considerable heterogeneity, so we





FIGURE 3 | The pooled effects of berberine-containing quadruple therapy on peptic ulcer healing rate. (A) Forest plot comparing berberine-containing quadruple treatment with the standard triple therapy. (B) Subgroup analysis about the treatment duration.



turned to a random effect model. As shown in **Figure 5A**, the experimental group significantly reduced the incidence of side events (RR 0.65; 95% CI 0.53 to 0.80; $I^2 = 58\%$). The results of the meta-regression showed that there was no difference regarding the publication year, the method, the PPI type, the total number of participants, the dose of berberine, and the time of treatment duration (shown in **Supplementary Figure 4**). The subgroup analyses regarding the time of treatment duration suggested no significance (**Figure 5B**). As shown in **Figure 5C**, the incidence of adverse events was significantly reduced in the subgroup (low dose = 120 mg) (RR 0.45; 95% CI 0.27 to 0.72).

Publication Bias

Publication bias was judged by Egger's tests in Stata 12.0. In Egger's tests, p > 0.05 was considered as no publication bias. The results showed that there was no bias in the analyses of adverse effects (p = 0.178), improvement of ulcers (p = 0.102) and relief rate of clinical symptoms (p = 0.084), except for *H. pylori* eradication rate (p = 0.000) (**Figure 6**). Even though the overall effect of the *H. pylori* eradication rate was significant, Egger's tests suggested the possibility of publication, and the pooled results need further verification.

DISCUSSION

In the past decade, the standard triple therapy consisting of a PPI and two antibiotics (clarithromycin and amoxicillin) was the most commonly used for clinical treatment for H. pylori infection in China. However, many clinical studies have shown that the initial Hp eradication rate of standard triple therapy is gradually decreasing, and the resistance of *H. pylori* to antibiotics is the main reason for its eradication failure (Papastergiou and Georgopoulos, 2014; Yang and Lu, 2014; Savoldi et al., 2018). Since then, bismuth combined with triple therapy has been proposed in China in 2012, but the addition of bismuth reduced patient compliance because of its high frequency of adverse events, such as vomiting, abdominal pain, black tongue, and diarrhea (Liu et al., 2012). The limited effectiveness of standard triple therapy and the side effect of bismuthcontaining quadruple therapy have forced researchers to consider alternative strategies to eliminate H. pylori infection. Many new strategies have been proposed, such as supplements of


probiotics and TCM. Studies of TCM on H. pylori have shown that some herbs such as R. coptidis, C. phellodendri, and berberine can inhibit H. pylori (Li et al., 2016). Many clinical trials have also shown that berberine, an antimicrobial, antidiabetic, anti-inflammatory, and antitumor drug can be used to treat H. pylori-induced chronic gastritis in vitro and in vivo (Chang et al., 2011; Lin et al., 2015; Tan et al., 2017; Wu et al., 2018). Furthermore, an open-label randomized phase IV trial showed that both bismuth-containing and berberinecontaining quadruple therapy achieved the recommended efficacy and can be recommended as the first-line treatment for H. pylori eradication in Xi'an, China (Zhang et al., 2017). Although many facts have shown that the addition of berberine in standard triple therapy can improve the eradication rate of H. pylori, reduce adverse events, and decrease costs (Li, 2011; Lu, 2018), the effects of berberinecontaining quadruple therapy of randomized controlled trials (RCTs) for H. pylori eradication are still controversial. Therefore, we conducted a systemic review and meta-analysis on the efficacy and safety of the addition of berberine in standard triple therapy on H. pylori eradication.

Our review is a systematic review about the efficacy of the addition of berberine in standard triple therapy on H. pylori eradication in China. Our results indicated that berberinecontaining quadruple therapy was more effective in terms of H. pylori eradication, peptic ulcer healing, and improvement of clinical symptoms. Compared with standard triple therapy (rabeprazole or omeprazole, amoxicillin, and clarithromycin), the addition of berberine in standard triple therapy significantly improved the Hp eradication rate. Although the Hp eradication rates were determined by different methods, either by histological RUT or the ¹³C/¹⁴C UBT, or a combination of both, all of them can effectively determine the eradication rate of Hp. The dose of berberine varied in these included studies, with most studies using 120 or 300 mg each time, one study using 400 mg each, and two studies using 500 mg each time, three times a day. In our subgroup analyses, we combined 300, 400, and 500 mg into one group and grouping the dose as low dose (120 mg) and high dose (\geq 300 mg). The result showed that the H. pylori eradication rate didn't increase with higher dose, but the dose of 120 mg had minimal side events.

H. pylori infection plays an important role in the pathogenesis of peptic ulcer disease (PUD). Bacterial adhesins and gastric

| $ \begin{array}{c} \operatorname{Com} 2013 & 10 & 140 & 8 & 125 & 4.0\% & 1.12 [0.45, 2.74] \\ \operatorname{Ha}(2015) & 14 & 30 & 17 & 50 & 6.5\% & 0.38 [0.51, 1.60] \\ \operatorname{Ha}(2015) & 14 & 30 & 17 & 80 & 6.5\% & 0.38 [0.51, 1.60] \\ \operatorname{Ha}(2015) & 14 & 30 & 17 & 80 & 13 & 80 & 3.5\% & 0.38 [0.51, 1.60] \\ \operatorname{Luc}(2017) & 15 & 81 & 13 & 81 & 3.5\% & 0.38 [0.51, 1.60] \\ \operatorname{Luc}(2017) & 15 & 81 & 13 & 81 & 3.5\% & 0.38 [0.51, 1.60] \\ \operatorname{Luc}(2013) & 27 & 210 & 81 & 220 & 13.1\% & 0.03 [0.51, 1.00] \\ \operatorname{Luc}(2013) & 27 & 210 & 81 & 220 & 13.1\% & 0.03 [0.51, 1.00] \\ \operatorname{Luc}(2013) & 27 & 210 & 81 & 220 & 13.1\% & 0.03 [0.51, 1.00] \\ \operatorname{Luc}(2013) & 27 & 210 & 81 & 220 & 13.1\% & 0.03 [0.51, 0.03] \\ \operatorname{Luc}(2017) & 14 & 150 & 44 & 60 & 2.1\% & 1.16 & 0.00 [0.5\% & 0.78] \\ \operatorname{Luc}(2017) & 14 & 150 & 44 & 60 & 2.1\% & 1.16 & 0.00 [0.5\% & 0.78] \\ \operatorname{Luc}(2017) & \operatorname{Luc}(2017) & \operatorname{Com} = 2.850 & \operatorname{dr} 12 (p = 0.005), p = 95\% & 1.16 & 1.00 \\ \operatorname{Luc}(2013) & 24 & 45 & 0.0 & 113 & 0.37\% & 0.38 [0.51, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.02 & 1.1\% & 1.00 & 0.08 [0.51, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.61, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.61, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.61, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.61, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.61, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.51, 0.00] \\ \operatorname{Luc}(2013) & 47 & 64 & 0.07 & 1.03\% & 0.03 [0.51, 0.00] \\ \operatorname{Luc}(2013) & 47 & 44 & 3.03\% & 44 & 25\% & 0.71 [0.56, 0.88] \\ \operatorname{Luc}(2017) & 14 & 0.01\% & 120 & 0.71\% & 0.04 (0.73\% & 0.03\% & 0.05\% & 0.03\% & 0.05\% & 0.03\% & 0.05\% & 0.03\%$ | Study or Subgroup | Experim Events | | Contr | | Woight | Risk Ratio IV. Random, 95% Cl | Risk Ratio IV. Random, 95% Cl |
|--|---|------------------------|-----------|-----------|-----------|--------------------------|----------------------------------|----------------------------------|
| $\begin{aligned} \begin{array}{l} 14 & 2015 & 14 & 43 & 31 & 17 & 53 & 6.9\% & 0.82 [0.45, 1.46] \\ 140 & 2017 & 45 & 68 & 13 & 14 & 12.5\% & 0.38 [0.51, 1.63] \\ 140 & 2017 & 45 & 68 & 13 & 42 & 12.5\% & 0.38 [0.51, 1.63] \\ 140 & 2017 & 45 & 68 & 13 & 42 & 12.5\% & 0.38 [0.51, 1.63] \\ 140 & 2018 & 2 & 25 & 12 & 65 & 12.4\% & 0.78 [0.56, 1.64] \\ 140 & 2018 & 24 & 25 & 01 & 24 & 00 & 2.1\% & 1.00 [0.5\%, 1.63] \\ 22mag (260)4 & 24 & 50 & 24 & 00 & 2.1\% & 1.00 [0.5\%, 0.64 [0.41, 0.63] \\ 22mag (260)4 & 24 & 50 & 2.2\% & 0.005, p = 55\% \\ 22mag (260)4 & 24 & 50 & 2.2\% & 0.005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 2M & 301 \\ Teal events & 100 & 12.0\% & 20.005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 100 & 12.0\% & 10005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 100 & 12.0\% & 10005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 100 & 12.0\% & 10005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 100 & 12.0\% & 10005, p = 55\% \\ Teal (errors) & 22M & 301 \\ Teal events & 100 & 14.20\% & 10005, p = 55\% \\ Teal (errors) & 24M & 301 & 12.0\% & 10005, p = 55\% \\ Teal (errors) & 24M & 301 & 0.37\% & 0.76 [0.55, 0.03] \\ 0.02 & 0.1 & 0.05\% & 0.64 [0.41, 0.30] \\ 0.02 & 0.1 & 0.05\% & 0.64 [0.41, 0.30] \\ 0.02 & 0.1 & 0.05\% & 0.07 [0.51, 0.64] \\ 0.02 & 0.1 & 0.05\% & 0.07 [0.51, 0.64] \\ 0.02 & 0.1 & 0.05\% & 0.07 [0.51, 0.64] \\ 0.02 & 0.1 & 0.05\% & 0.07 [0.51, 0.64] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.42, 0.17] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.42, 0.17] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.42, 0.17] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.42, 0.17] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.42, 0.43] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.43, 0.63] \\ 0.02 & 0.1 & 0.05\% & 0.04 [0.52, 0.79] \\ 0.02 & 0.05\% & 0.00\% & 0.04 [0.52, 0.79] \\ 0.02 & 0.05\% & 0.00\% & 0.04 [0.52, 0.79] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01 & 0.1 & 0.0\% & 0.00\% & 0.00\% & 0.04 [0.02, 0.07] \\ 0.01$ | | | | | | | | |
| $\frac{1}{102} \frac{2017}{2013} \frac{19}{10} \frac{9}{10} 9$ | | | | | | | 0.38 [0.15, 1.00] | |
| La 2017 La 2017 La 2017 La 2017 La 2017 La 2013 La 2017 La 2013 La 2014 La 2014 La 2014 La 2014 La 2014 La 2017 La 2014 La 2014 La 2017 La 2014 La 2017 La 2014 La 2017 La 2014 La 2017 La 2014 La 2017 La 2014 La 2017 La 2016 La 2013 La 2017 La | | | | | | | | |
| $ \begin{array}{c} M_{2} \ (2) 1 \\ M_{2} $ | | | | | | | | - |
| $ \begin{array}{c} Ma 2016 \\ 2013 \\ 2013 \\ 0 \\ 0 \\ 2013 \\ 0 \\ 0 \\ 1 \\ 1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2$ | Luo 2017 | 5 | 81 | 13 | 81 | 3.5% | 0.38 [0.14, 1.03] | |
| $ \begin{array}{c} 0.203 & pr \\ 2203 & 24 & 48 \\ 2203 & 24 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 80 & 33 & 48 \\ 2204 & 21 & 30 & 21 \\ 2204 & 21 & 30 & 21 \\ 2204 & 21 & 21 & 228 & 58 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 21 & 21 & 21 \\ 2204 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2204 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2204 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2204 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2204 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2004 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2004 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2004 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2004 & 21 & 22 & 54 & 31 & 42 & 119 \\ 2004 & 21 & 21 & 21 & 200 \\ 2004 & 21 & 21 & 200 \\ 2004 & 21 & 21 & 200 \\ 2004 & 21 & 200 & 21 \\ 1002 & 410 & 410 \\ 100 & 412 & 410 \\ 100 & 412 & 410 \\ 100 & 412 & 410 \\ 100 & 412 & 410 \\ 100 & 412 & 410 \\ 100 & 410 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 10 & 412 \\ 100 & 201 & 201 & 10 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 201 \\ 100 & 201 & 201 & 2$ | | | | | | | | |
| Si 2013 2 4 4 6 30 45 114% 0.80 [0.57, 1.13] Zhang 322014 16 100 62 100 8.5% 0.28 [0.16 0.41] Zhang 322013 4 50 0 4 50 210 0.5% 0.65 [0.5, 0.89] Under each 24 391 Heterogeneity: Tat = 0.07, 10 ⁴ = 28.50, d = 12 (P = 0.050); P = 58% Test for overall effect: 2 = 4.1 (P < 0.0001) B Status of the state overall effect: 2 = 4.1 (P < 0.0001); P = 38% 10.0 2 0.1 1 0 0 50 Favours [seperimental] Favours [control] State overall effect: 2 = 4.1 (P < 0.0001); P = 38% 10.0 2 0.1 1 0 0 50 Favours [seperimental] Favours [control] State overall effect: 2 = 4.1 (P < 0.0001); P = 42% Test for overall effect: 2 = 4.1 (P < 0.0001); P = 42% Test for overall effect: 2 = 4.1 (P < 0.0001); P = 42% Test for overall effect: 2 = 4.1 (P < 0.0001); P = 42% Test for overall effect: 2 = 3.50 (P = 0.0001); P = 42% Test for overall effect: 2 = 3.50 (P = 0.0001); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 4.10 (P = 0.0001); P = 55%; Test for overall effect: 2 = 4.10 (P = 0.0001); P = 55%; Test for overall effect: 2 = 4.10 (P = 0.0001); P = 55%; Test for overall effect: 2 = 4.10 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0002); P = 65%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overall effect: 2 = 2.73 (P = 0.0001); P = 55%; Test for overal | | | | | | | | - |
| Zhang X20214 16 100 82 100 8.8% 0.22 [0.16, 0.41] Tatal 69% CD 1072 1039 100.0% 0.65 [0.53, 0.40] Jatal 69% CD 1072 1030 100.0% 0.65 [0.53, 0.40] Jatal 60% CD 1072 100 100.0% 0.71 [Jatal 60% 0.63] Jatal 60% CD 1072 100 100.0% 0.71 [Jatal 60% 0.63] Jatal 60% CD 1074 100 100 100 100.0% 0.71 [Jatal 60% 0.63] Jatal 60% CD 1074 100 100 20% 0.71 [Jatal 60% 0.63] Jatal 60% CD 1074 100 100 20% 0.71 [Jatal 60% 0.63] Jatal 60% CD 1072 1039 100.0% 0.64 [0.52, 0.79] Jatal 60% | | | | | | | | |
| Zou 2013 4 90 4 90 2.1% 1.00 [0.28, 3.78] Test of (5%) Cl 2013 4 90 4 90 2.1% 0.05 [0.53, 0.89] Test of versal effect 2 = 4.14 ($P < 0.0001$) $P = 68%$ Test for overall effect 2 = 4.14 ($P < 0.0001$) $P = 68%$ B Subtrace Subtrace Test Test of the test of t | | | | | | | | |
| Total events 204 Total events 204 Total events 204 Total events 204 Total events 204 Total events 204 Total events 207 CD ⁻¹ 208.0, df = 12 (P = 0.000), P = 58% Total coveral effect 2 = 4.1 (P = 0.0001) B Subcover events 4 = 0.0001 Total events 2 = 4.1 (P = 0.0001) Experimental Control Risk Ratio Subcover events 4 = 0.0001 Total events 2 = 4.1 (P = 0.0001) Total events 2 = 4.1 (P = 0.0001) Total events 2 = 5.0 = 1.3 56 3.7% 0.32 (0.14, 0.15) Subcover events 4 = 0.0000 Total events 1 = 0.00000 Total events 1 = 0.0000 Total events 1 = 0.00000 Total events 1 = 0.0000 Total events 1 = 0.00000 Total events 1 = 0.00000 Total events 1 = 0.00000 Total events 1 = 0.00000 Total events 1 = 0.000000 Total events 1 = 0.000000 Total events 1 = 0.000000000000000000000000000000000 | | | | | | | | |
| Total events 2244 391 Heterogeneity: Tar 2 0.07, Ch ² = 2260, df = 12 (P = 0.005); P = 98% Test for overall effect 2 = 4.14 (P < 0.0001) B Subtract or Subgroup Events Total Events Total Weight M-H. Random, 95% CI 1.10, 174ys Dong 2013 5 50 13 50 3.7% 0.38 [0 15, 1.00] La 2013 47 84 69 76 13.7% 0.74 [0.56, 0.38] La 2013 47 84 69 76 13.7% 0.74 [0.56, 0.38] La 2013 2 55 12 55 1.9% 0.03 [0.41, 0.71] Subtract (9% CI) 44 6 49 71 13.6% 0.38 [0.41, 0.71] La 2013 10 42 55 12 55 1.9% 0.71 [0.56, 0.88] Ma 2011 2 5 51 2 55 1.9% 0.71 [0.56, 0.88] La 2013 67 2.21 0 81 2.21 0.30% 0.38 [0.41, 0.71] Subtract (9% CI) 44 6 3 125 4.1% 1.2 [0.45, 2.74] Haang 2017 18 100 22 100 8.1% 0.46 (0.38, 1.48] La 2013 10 40 81 22 5.03 (P = 0.002) 1.10.2 14days Chen 2013 10 140 8 125 4.1% 1.2 [0.45, 2.74] Haang 2017 18 100 22 100 8.1% 0.46 (0.38, 1.48] La 2017 5 81 61 31 81 3.8% 0.38 [0.41, 1.03] La 2013 4 50 4 50 2.2% 10.06 8.1% 0.46 (0.38, 1.48] La 2017 5 81 61 31 81 3.8% 0.38 [0.41, 1.03] La 2013 4 50 4 55 2.2% 10.06 8.1% 0.46 (0.38, 1.48] La 2017 5 81 6 13 81 3.8% 0.38 [0.41, 1.03] La 2013 4 50 4 50 2.2% 10.00 8.1% 0.46 (0.52, 0.79] La 2033 4 50 4 50 2.2% 10.00 (D [2.8, 3.78] Subtract (9% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] La 2033 4 50 1.06% 0.52 [0.06, 0.41] La 2031 4 55 5 1.106% 0.52 [0.000]; P = 6% Test for overall effect Z = 2.30 (P = 1.2 (P = 0.004); P = 9% Total events 12 La 2031 7 28 54 33 7 0 3.3% 0.38 [0.51, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.51, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.51, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.51, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.54, 1.07] Subtract (95% CI) 1072 102 Forest Total Weight M-H, Random, 95% CI La 2033 7 8 50 133 50 3.7% 0.38 [0.54, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.54, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.54, 1.00] La 2033 7 8 50 133 50 3.7% 0.38 [0.54, 1.00] La 2033 7 7 80 4 33 7 80 3.7% 0.38 [0.54, 1.00] La 2033 7 7 80 4 33 7 80 3.7% 0.38 [0.54, 1.00] La 2033 7 7 80 4 33 7 80 3.7% 0.38 [0.54, 1.00] La | | | | | | | | • |
| $\begin{aligned} & \text{Heterogeneity: Tarl = 0.07, Ch^{2} = 28.50, df = 12 (p = 0.005); P = 58% \\ \hline begin{tabular}{lllllllllllllllllllllllllllllllllll$ | | 264 | 1072 | 201 | 1039 | 100.0% | 0.65 [0.53, 0.80] | • |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | Heterogeneity: Tau ² = | 0.07; Chi ² | | df = 12 (| P = 0.0 | 05); I² = 58 | 3% H | |
| Study coup Events Total Weight M-H. Random, 95% Cl M-H. Random, 95% Cl Dong 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Log 101 28 54 31 42 11.9% 0.77 [0.55, 0.96] Ma 2016 2 55 12 55 12.95 1.9% 0.71 [0.64, 0.71] Q 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Q 2013 67 210 81 212 13.0% 0.83 [0.64, 1.07] Q 2015 140 53 41.4% 1.12 [0.45, 2.74] 1.112 [0.45, 2.74] Huang 2017 18 100 2.8 100.8, 1.08 [0.61, 1.03] 1.112 [0.45, 2.74] Huang 2017 18 100 2.8 10.08 [0.57, 1.13] 1.112 [0.45, 2.74] Log 2013 2.4 4.5 30 10.64 [0.52, 0.79] 1.112 [0.45, 2.74] Huang 2017 18 100 2.8 0.62 [0.44, 0.87] 1.112 [0.45, 2.74] | В | | | | | | | |
| 1.10.1 Tadays Dong 2013 5 5 0 13 50 3.7% 0.38 [0.15, 1.00] 1.10.213 47 84 59 78 13.7% 0.74 [0.56, 0.63] Ma 2011 28 54 31 42 11.9% 0.75 [0.51, 0.69] Ma 2013 67 210 81 2 10 13.0% 0.83 [0.41, 0.71] Subtal (95% CI) 43 43 44.2% 0.71 [0.56, 0.88] 1.10 14 events 149 196 Heterogeneity: Tau ² = 0.02; Ch ² = 8.8, df = 4 ($P = 0.14$); $P = 4.2\%$ Tatal events 2 3.03 ($P = 0.002$) 1.10.2 14days Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Heterogeneity: Tau ² = 0.02; Ch ² = 8.8, df = 4 ($P = 0.14$); $P = 4.2\%$ Tatal events 10 10 160 8 15% 0.38 [0.44, 1.03] 2.20 2017 18 100 26 100 8.9% 0.38 [0.44, 0.03] 2.20 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtata (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 21 3.03 ($P = 0.000$); $P = 65\%$ Total events 21 3.03 ($P = 0.000$); $P = 0.5\%$ Total events 21 3 15 0 1.7% 0.38 [0.44, 0.67] Total events 21 3 15 0 1.7% 0.38 [0.44, 0.67] Total events 21 3 15 0 1.2% 1.00 [0.26, 3.78] Subtata (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Heterogeneity: Tau ² = 0.7; Ch ² = 28.20, df = 12 ($P = 0.004$); $P = 65\%$ Total events 21 3 10 1.00 Tata for subbroup differences: Ch ² = 0.11 dt events Total Weight M + h, Random, 55% CI M-H, Ran | | Experim | iental | Cont | rol | | Risk Ratio | Risk Ratio |
| Dong 2013 5 5 00 13 50 3.7% 0.38 [0.15, 1.00] Ma 2011 28 54 31 42 11.9% 0.70 [0.57, 0.96] Ma 2016 2 55 12 55 12 55 1.9% 0.70 [0.57, 0.96] Ma 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Old 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Total events 149 196 Heterogenety: Tau ² = 0.02; Ch ² = 8.8; df = 4 (P = 0.14;)P = 42% Heterogenety: Tau ² = 0.20; Ch ² = 8.8; df = 4 (P = 0.14;)P = 42% Heterogenety: Tau ² = 0.20; Ch ² = 8.8; df = 4 (P = 0.14;)P = 42% Heterogenety: Tau ² = 0.20; Ch ² = 8.8; df = 4 (P = 0.14;)P = 42% Huang 2017 16 10 16 0 6 125 4.1% 112 [0.45, 2.74] Huang 2017 16 10 26 100 8.1% 0.64 [0.30, 810 14, 100] Si 2013 2 44 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang XX2014 16 100 62 100 8.9% 0.28 [0.16, 0.41] Zhang XX2014 16 100 62 100 8.9% 0.28 [0.16, 0.41] Zhang XX2014 16 100 62 100 8.9% 0.28 [0.16, 0.41] Zhang XX2014 16 100 62 100 8.9% 0.62 [0.44, 0.87] Total events 112 195 Total events 112 197 1039 100.0%, 0.64 [0.52, 0.79] Total events 112 197 1039 100.0%, 0.64 [0.52, 0.79] Total events 112 197 1039 100.0%, 0.64 [0.52, 0.79] Total events 113 190 127 1039 100.0%, 0.64 [0.52, 0.79] Total events 113 190 127 1039 100.0%, 0.64 [0.52, 0.79] Total events 113 190 0.00; Ch ² = 59% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P = 0.0001); P = 69% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P = 0.0001); P = 81% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P = 0.0001); P = 81% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P = 0.0001); P = 81% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P = 0.0001); P = 81% Total events 103 190 Heterogenetry: Tau ² = 0.24, Ch ² = 20, df = 12 (P = 0.0001); P = 81% Total events 103 200 21 00 8.1% 0.64 (0.35, 1.06) Mather 2.24, 1.04 0.25, Ch ² = 20, df = 12 (P = 0.0001); P = 81% Total e | | | | | | Weight | | |
| Lu 2013 47 84 59 78 13.7% 0.74 [0.56, 0.93] 48 2011 28 54 31 42 11.9% 0.70 [0.51, 0.96] 48 2016 2 55 12 55 1.9% 0.71 [0.40, 0.71] 5.ubtola (095% C) 453 435 44.2% 0.71 [0.56, 0.88] 44 2% 0.82 [0.44, 1.49] 44 2015 14 40 3 17 35 7.7% 0.82 [0.44, 0.87] 44 50 45 11.4% 0.82 [0.44, 0.87] 45 20 2013 4 50 4 50 2.2% 100 [0.26, 3.78] 50 2013 4 50 4 50 2.2% 100 [0.26, 3.78] 50 2013 4 50 4 50 2.2% 100 [0.26, 3.78] 50 2013 4 50 4 50 2.2% 100 [0.26, 3.78] 50 2013 4 50 4 50 2.2% 100 [0.26, 3.78] 50 20 1 107 107 109 100.% 0.64 [0.52, 0.79] 40 01 0.1 1 0.1 100 50 006 1 2 0.004); P = 05% Total events 112 195 Heterogeneity: Tau" = 0.07, Ch" = 28 20, df = 12 (P = 0.004); P = 05% Total events 261 391 10 0 1 0.1 1 0.1 100 Favours [experimental] Favours [control] 50 13 15 0 3.7% 0.38 [0.14, 1.06] 40 01 0.1 1 0.1 100 50 13 13 50 3.7% 0.38 [0.15, 1.00] 40 01 0.1 1 0.1 100 50 13 13 13 3.6% 0.72 (1.55, 0.03] 40 01 0.1 1 0.1 100 50 13 0.1 12 0.03 13 0.0 8.0 0.43 (0.15, 1.00] 50 2013 2 12 55 1.2 55 1.2 % 0.38 [0.14, 0.63] 40 46 43.56% 0.45 [0.27, 0.72] 50 20 107 28 54 31 34 3.6% 0.38 [0.15, 1.00] 40 46 43.56% 0.45 [0.27, 0.72] 51 20 20 107 28 54 31 34 3.6% 0.38 [0.15, 1.00] 51 20 400 51 0.64 2.5 55 1.2 % 0.38 [0.14, 0.63] 51 20 400 6 2.0 509 51 20 3 10 10 40 8 125 4.1% 1.12 [0.45, 2.74] 51 20 20 1 74 28 54 31 34 3.6% 0.45 [0.27, 0.72] 51 20 20 1 74 28 54 31 34 3.6% 0.45 [0.27, 0.72] 51 20 20 1 74 28 54 31 34 3.6% 0.45 [0.27, 0.72] 51 20 20 1 74 28 54 31 34 3.6% 0.45 [0.27, 0.72] 51 20 20 1 74 28 54 31 34 3.6% 0.45 [0.27, 0.72] 51 20 20 1 74 29 20, df = 12 (P | | F | 50 | 40 | 50 | 2 70/ | 0.39 10 45 4 001 | |
| Ma 2011 28 54 31 42 11.9% 0.70 [0.51, 0.69] Ma 2016 2 55 11 25 1.1% 0.71 [0.64, 0.71] G1 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] G1 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Total events 149 196 Heterogeneity: Tav' = 0.02; Ch ² = 6.85, df = 4 (P = 0.14); P = 42% Test for overall effect: Z = 3.03 (P = 0.002) 1.10.2 14days Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.08] Luc 2017 5 81 13 81 3.8% 0.38 [0.14, 1.03] S12013 24 44 30 04 51 14.4% 0.80 [0.57, 1.13] Zhang X2014 15 100 82.5% 0.22 [0.16, 0.41] Zu 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtatal (Bfw; Cl) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 221 195 50 .000;) T = 65% Test for overall effect: Z = 4.19 (P = 0.004); P = 65% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 0.52); P = 0% C C Experimental Control Risk Ratio Study or subgroup Events Total Events Total Weight M-H, Random, 95% Cl M = 44 53 00 455 0.78 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 79 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 79 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 79 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 79 13.7% 0.38 [0.16, 1.07] Total (95% Cl) 16 48 63 50.46 (0.45, 0.45] Ju 2013 47 45 50 71 5 4.1% 112 [0.45, 2.74] Heterogeneity: Tau' = 0.24; Ch ² = -0.52, If = 0.06 Heterogeneity: Tau' = 0.24; Ch ² = -0.52, If = 0.06 Heterogeneity: Tau' = 0.24; Ch ² = -0.52, If = 0.06 Het | | | | | | | | - |
| Gi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Total events 149 196 Heterogeneity: Tar 0.02; Ch ² = 6.85, df = 4 (P = 0.14); P = 42% Test for overall effect: Z = 3.03 (P = 0.002) 1.10.2 14days Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.49] Hu 2017 18 100 2.8 100 8.1% 0.64 [0.33, 1.08] Luc 2017 5 81 13 81 3.8% 0.38 [0.14, 1.03] Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang X2014 15 100 8.2% 0.006); P = 65% Total events 12 Total events 12 Total events 2014 [10 0 62 (0.006); P = 65% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.004); P = 55% Test for overall effect: Z = 4.19 (P = 0.0001) Test for suboroup differences: ChP = 0.41. df = 1 (P = 0.52); P = 0% C C C C C C C C C C C C C | Ma 2011 | 28 | | | | | | |
| Subtol (95% C) 453 435 44.2% 0.71 [$0.56, 0.88$] Heterogeneity: Tau" = 0.02; ChP = 6.45, df = 4 (P = 0.14); P = 42%, Test for overall effect: Z = 3.03 (P = 0.002) 1.10.2 144ays Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.34, 1.03] Jamag G2014 21 150 33 50 10.6% 0.64 [0.43, 0.93] Zhang X2014 16 100 62 100 8.9% 0.26 [0.16, 0.41] Zu 2013 4 450 4 50 2.2% 1.00 [0.25, 3.78] Subtol (95% C) 619 604 55.8% 0.62 [0.44, 0.87] Total events 112 195 Heterogeneity: Tau" = 0.14; ChF = 29.20, df = 12 (P = 0.004); P = 65% Test for overall effect: Z = 2.73 (P = 0.004); 1P = 65% Test for overall effect: Z = 2.73 (P = 0.004); 1P = 65% Test for overall effect: Z = 2.73 (P = 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 65% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 55% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 55% Test for overall effect: Z = 4.19 (P < 0.004); 1P = 55% Test for overall effect: Z = 2.73 (P = 0.004); 1P = 55% Test for overall effect: Z = 2.73 (P = 0.004); 1P = 55% Test for overall effect: Z = 3.26 (P = 0.01); 13 = 3.7% 0.38 [0.15, 1.00] Log 13 47 84 59 7 13.7% 0.38 [0.15, 1.00] Log 13 10 40 52 51 13 50 3.7% 0.38 [0.14, 1.03] Heterogeneity: Tau" = 0.24; Ch ² = 2.53, df = 5 (P < 0.0001); 1 ² = 81% Test for overall effect: Z = 3.26 (P = 0.001); 1 ² = 81% Test for overall effect: Z = 3.26 (P = 0.0021) Total (95% C) 12 21 18 100 128 100 3.64 1.03 3.108 (Q 2013 67 21 08 11 20 13.06 0.64 [0.43, 0.38 10.44, 1.07] Huang 2017 18 100 28 100 8.105 0.22% Total (95% C) 12 21, df = 6 (P = 0.66); 1 ² = 0% Total (95% C) 10 12 2 103 100 0.64 0.64 (0.57, 0.13] Heterogeneity: Tau" = 0.07; Ch ² = 2.92, df = 1 2 (P = 0.0001); 1 ² = 81% Test | | | | | | | | |
| Total events 149 196 Heterogeneily: Tau ² = 0.02; Ch ² = 6.8, df = 4 (P = 0.14); P = 42% Test for overall effect: Z = 3.03 (P = 0.002) 1.10.2 14days Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.49] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.49] Hu 2017 15 81 13 81 3.6% 0.38 [0.14, 1.03] Zhang X2014 16 100 62 100 8.9% 0.26 [0.6, 0.41] Zou 2013 24 45 30 45 114.4% 0.80 [0.57, 1.13] Zhang X2014 16 100 62 100 8.9% 0.64 [0.43, 0.83] Total events 21 395 Heterogeneily: Tau ² = 0.07; Ch ² = 29.00, df = 12 (P = 0.006); P = 65% Test for overall effect: Z = 4.19 (P = 0.006); P = 65% Total events 261 391 Heterogeneily: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Total events 261 391 Heterogeneily: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Total events 261 391 Heterogeneily: Tau ² = 0.07; Ch ² = 28.20, df = 12 (P = 0.004); P = 69% C Subtotal effect: Z = 4.19 (P = 0.006); P = 0.52), P = 0% C Subtotal events 261 391 Heterogeneily: Tau ² = 0.24; Ch ² = 2.53, df = 5 (P < 0.0001); I ² = 818 Test for overall effect: Z = 4.19 (P < 0.0001); I ² = 818 Test for overall effect: Z = 4.19 (P < 0.0001); I ² = 818 Test for overall effect: Z = 4.19 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 818 Test for overall effect: Z = 3.26 (P < 0.0001); I ² = 95% Total events 158 Subtotal (95% C) 1072 1039 100.0% 6.64 [0.52, 0.79] Total events 261 Total events 261 Total events 261 S10 100 Ch ² = 22.00, df = 12 (P = 0.004); I | | 67 | | 81 | | | | |
| $\begin{aligned} & \text{Heterogeneity: Tau^2 = 0.02; Chi^2 = 6.85, df = 4, (P = 0.14); P = 42% \\ & \text{Test for overall effect Z = 3.03 (P = 0.002) \\ \hline 1.0.2 14days \\ & \text{Chen 2013} & 10 & 140 & 8 & 125 & 4.1\% & 1.12 [0.45, 2.74] \\ & \text{Huang 2017} & 18 & 100 & 28 & 100 & 8.1\% & 0.64 [0.38, 1.08] \\ & \text{Huang 2017} & 18 & 100 & 28 & 100 & 8.1\% & 0.64 [0.38, 1.08] \\ & \text{Luo 2017} & 5 & 81 & 13 & 81 & 3.6\% & 0.38 [0.41, 1.03] \\ & \text{Subtool (5% C)} & 619 & 604 & 55.8\% & 0.32 [0.44, 0.87] \\ & \text{Subtool (5% C)} & 619 & 604 & 55.8\% & 0.62 [0.44, 0.87] \\ & \text{Total events} & 112 & 195 \\ & \text{Heterogeneity: Tau^2 = 0.14; Chi^2 = 29.20, df = 7 (P = 0.004); P = 59\% \\ & \text{Test for overall effect: Z = 2.73 (P = 0.006) \\ \hline & \text{Total events} & 12 & 195 \\ & \text{Heterogeneity: Tau^2 = 0.07; Chi^2 = 29.20, df = 7 2 (P = 0.004); P = 59\% \\ & \text{Test for overall effect: Z = 2.73 (P = 0.006) \\ \hline & \text{Total events} & 1072 & 1039 & 100.0\% & 0.64 [0.52, 0.79] \\ & \text{Total events} & 112 & 195 \\ & \text{Heterogeneity: Tau^2 = 0.07; Chi^2 = 29.20, df = 12 (P = 0.004); P = 59\% \\ & \text{Test for overall effect: Z = 4.10 (P < 0.52), P = 0.9\% \\ \hline & \text{Total events} \\ & \text{Total events} & Tota$ | | 149 | 400 | 196 | 400 | 44.2 /0 | 0.77 [0.00, 0.00] | • |
| Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.45, 1.49] Lu 2017 5 81 13 81 3.6% 0.38 [0.45, 1.08] Lu 2017 5 81 13 81 3.6% 0.38 [0.41, 1.03] Zhang X2014 16 100 62 100 8.9% 0.26 [0.16, 0.41] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal [9% CI) 619 664 55.8% 0.62 [0.44, 0.87] Total events 261 391 Heterogeneity: Tau ² = 0.07; Ch ² = 2.620, df = 12 (P = 0.004); P = 59% Test for overall effect: $Z = 2.73 (P = 0.006)$ Total events 261 391 Heterogeneity: Tau ² = 0.07; Ch ² = 2.620, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 19 (P < 0.007) Total events 261 391 Heterogeneity: Tau ² = 0.07; Ch ² = 2.820, df = 12 (P = 0.004); P = 59% Statustical (20mg) Dong 2013 5 50 13 50 3.7% 0.74 (0.59, 0.93] Lu 2013 4 5 50 13 50 3.7% 0.74 (0.59, 0.93] Lu 2013 5 50 13 50 3.7% 0.74 (0.74 (0.59, 0.93]) Dong 2013 5 50 13 50 3.7% 0.74 (0.74 (0.59, 0.93]) Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 5 10 13 60 - 2 55 12 55 1.9% 0.75 (0.74 (0.41, 0.31) Ma 2011 5 81 13 81 3.6% 0.38 (0.14, 1.03] Ma 2016 2 55 12 2 55 1.9% 0.77 (0.74 (0.44, 1.03)) Heterogeneity: Tau ² = 0.24; Ch ² = 26.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 2.32 (f = 12 (P = 0.0001); l ² = 81% Test for overall effect: 2 = 3.25 (f = 5 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 3.25 (f = 6 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 3.25 (f = 0.002) Total events 158 201 Heterogeneity: Tau ² = 0.00; Ch ² = 2.6.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 3.26 (f = 0.002) Total events 158 201 Heterogeneity: Tau ² = 0.00; Ch ² = 2.6.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 3.26 (f = 0.002) Total events 158 201 Heterogeneity: Tau ² = 0.00; Ch ² = 2.6.25, df = 12 (P = 0.004); l ² = 59% Total events 158 201 Heterogeneity: Tau ² = 0.00; Ch ² = 2.6.25, df = 12 (P = 0.004); l ² = 59% Heterogeneity: Tau ² = 0.00; Ch ² = 2.92,0 (f = 12 (P = 0.004); l ² = 59% Heterogeneity: Tau | Heterogeneity: Tau ² = | | | | = 0.14) | ; I² = 42% | | |
| $ \begin{aligned} & Lu 2015 & 14 & 53 & 17 & 53 & 7.0\% & 0.82 [04.5, 1.49] \\ Lu 2017 & 5 & 81 & 13 & 81 & 3.6\% & 0.38 [0.41, 1.03] \\ Lu 2017 & 5 & 81 & 13 & 81 & 3.6\% & 0.38 [0.41, 1.03] \\ Zhang GF2014 & 21 & 50 & 33 & 50 & 10.6\% & 0.64 [0.57, 1.13] \\ Zhang X2014 & 16 & 100 & 62 & 100 & 8.9\% & 0.26 [0.46, 0.47] \\ Zhang X2014 & 16 & 100 & 62 & 100 & 8.9\% & 0.26 [0.46, 0.47] \\ Zhang X2014 & 16 & 100 & 62 & 100 & 8.9\% & 0.26 [0.44, 0.87] \\ Subtolal (95% CI) & 619 & 604 & 55.6\% & 0.62 [0.44, 0.87] \\ Total events & 112 & 195 \\ Heterogeneity: Tau2 = 0.14, Ch2 = 1.9.00, df = 7 (P = 0.004); P = 65\% \\ Test for overall effect: Z = 2.73 (P = 0.005) \\ Total (95% CI) & 1072 & 1039 & 100.0\% & 0.64 [0.52, 0.79] \\ Total events & 261 & 391 \\ Heterogeneity: Tau2 = 0.07; Ch2 = 2.20, df = 12 (P = 0.004); P = 59\% \\ Test for overall effect: Z = 4.19 (P < 0.0001) \\ Test for overall effect: Z = 4.19 (P < 0.0001) \\ Test for overall effect: Z = 2.13 (P = 0.004); P = 0.52), P = 0\% \\ C \\ C \\ C \\ C \\ C \\ C \\ Total (95% CI) & 1072 & 1039 & 100.0\% & 0.38 [0.15, 1.00] \\ Lu 2013 & 5 & 50 & 13 & 50 & 3.7\% & 0.74 [0.59, 0.93] \\ Lu 2013 & 5 & 50 & 13 & 50 & 3.7\% & 0.74 [0.59, 0.93] \\ Lu 2013 & 5 & 51 & 12 & 55 & 1.2\% & 0.74 [0.59, 0.93] \\ Lu 2013 & 5 & 51 & 12 & 55 & 1.2\% & 0.74 [0.59, 0.93] \\ Lu 2013 & 5 & 51 & 12 & 55 & 1.2\% & 0.74 [0.59, 0.93] \\ Lu 2013 & 5 & 51 & 12 & 55 & 1.2\% & 0.74 [0.59, 0.38] \\ Lu 2013 & 5 & 50 & 13 & 50 & 3.7\% & 0.74 [0.51, 0.96] \\ Hetrogeneity: Tau2 = 0.24; Ch2 = 2.62, df = 5 (P < 0.0001); I2 = 81\% \\ Test for overall effect: Z = -3.25, df = 5 (P < 0.0001); I2 = 81\% \\ Test for overall effect: Z = -3.21, df = 6 (P = 0.65); I2 = 0.05 (1.50, 1.13) \\ Hetrogeneity: Tau2 = 0.07; Ch2 = 2.92, 0 df = 12 (P = 0.004); I2 = 59\% \\ Total events & 158 & 201 \\ Heterogeneity: Tau2 = 0.07; Ch2 = 2.92, 0 df = 12 (P = 0.004); I2 = 59\% \\ Total events & 158 & 201 \\ Heterogeneity: Tau2 = 0.07; Ch2 = 2.92, 0 df = 12 (P = 0.004); I2 = 59\% \\ Total events & 158 & 201 \\ Heterogeneity: Tau2 = 0.07; Ch2 = 2.92, 0 df = 12$ | 1.10.2 14days | | | | | | | |
| Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Jung 2017 5 8 81 13 81 3.6% 0.38 [0.14, 1.03] Zhang 2F2014 21 50 33 50 106% 0.64 [0.43, 0.03] Zhang X2014 16 100 62 100 8.9% 0.26 [0.46, 0.41] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (9% CI) 619 664 55% 0.62 [0.44, 0.57] Total events 112 195 Helerogeneity: Tau ² = 0.17; Chi ² = 28.20, df = 12 ($P = 0.004$); $P = 59\%$ Test for overall effect: Z = 2.73 ($P = 0.006$); $P = 0.004$; $P = 59\%$ Test for overall effect: Z = 2.73 ($P = 0.006$); $P = 0.004$; $P = 59\%$ Test for overall effect: Z = 10 ($P < 0.0001$) Test for subarous differences: Chi ² = 0.41, df = 1 ($P = 0.52$); $P = 0\%$ C C Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 3.11 Low dose (120mg) Dong 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Data 2013 5 50 13 60 3.7% 0.38 [0.15, 1.00] Data 2013 5 50 13 50 3.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.7% 0.74 (0.59, 0.93] Lu 2013 47 84 59 75 13.2% 0.77 (0.64, 0.71] Subta 49% CI 445 30 45 11.4% 0.88 (0.64 [0.52, 0.72] Total events 103 Favoraneity: Tau ² = 0.02; Chi ² = 26.2; df = 5 (P < 0.0001); t ² = 81% Test for overall effect: Z = 3.11 (P = 0.002) Total events 158 201 Heterogeneity: Tau ² = 0.07; Chi ² = 25.0; df = 6 (P = 0.001); t ² = 59% Lu 2013 47 52 10 1072 1039 100.0% 0. | | | | | | | | _ |
| Luo 2017 5 81 13 81 3.6% 0.38 [0.41, 1.03] Zhang XX2014 16 100 62 100 8.9% 0.26 [0.46, 0.41] Zhang XX2014 16 100 62 100 8.9% 0.26 [0.46, 0.41] Zhang XX2014 16 100 62 100 8.9% 0.26 [0.44, 0.87] Subtotal (95% CI) 619 664 55.8% 0.62 [0.44, 0.87] Total events 112 195 Heterogeneity: Tau ² = 0.14; Chi ² = 19.90, df = 7 (P = 0.006); P = 65% Test for overall effect: Z = 4.19 (P < 0.0001) Total events 261 391 Heterogeneity: Tau ² = 0.14; Chi ² = 19.90, df = 1 (P = 0.52); P = 6% Test for overall effect: Z = 4.19 (P < 0.0001) Total (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.7; Chi ² = 29.20, df = 12 (P = 0.024); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for subarous differences: Chi ² = 0.41, df = 1 (P = 0.52); P = 0% C Subtotal (95% CI) Experimental Control Kisk Ratio Subtotal (95% CI) Experimental Control Kisk Ratio Subtotal (95% CI) 424 453 37% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.74 [0.59, 0.93] Ma 2011 5 81 13 81 3.6% 0.38 [0.14, 1.03] Ma 2011 5 81 13 81 3.6% 0.38 [0.14, 1.03] Ma 2011 5 81 13 81 3.6% 0.45 [0.27, 0.72] Total events 103 100 140 8 125 4.1% 1.12 [0.45, 2.74] Heterogeneity: Tau ² = 0.24; Chi ² = 26.52, f = 5 (P < 0.0001); l ² = 81% Test for overall effect: Z = 3.26 (P = 0.001) 31.2 High dose (2300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.149] Heterogeneity: Tau ² = 0.00; Chi ² = 25.2, df = 6 (P = 0.001); l ² = 81% Test for overall effect: Z = 3.21, df = 6 (P = 0.601); l ² = 05% Total events 15 201 Total events 15 201 Heterogeneity: Tau ² = 0.00; Chi ² = 25.1, df = 6 (P = 0.601); l ² = 51% Total events 15 201 Total events 15 201 Heterogeneity: Tau ² = 0.00; Chi ² = 22.0, df = 12 (P = 0.004); l ² = 59% Total events 167 201 Heterogeneity: Tau ² = 0.00; Chi ² = 25.0, df = 12 (P = 0.004); l ² = 59% Total events 167 Heterogeneity: Tau ² = 0. | | | | | | | | |
| Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang GZ014 21 50 33 50 106% 0.64 [0.43, 0.33] Zhang X2014 16 100 62 100 8.9% 0.26 [0.46, 0.41] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal [95% CI) 619 604 55.% 0.62 [0.44, 0.57] Total events 112 195 Heterogeneity: Tau ² = 0.1% (D ¹ P = 19.90, d ² T (P = 0.006); P = 65% Test for overall effect: Z = 2.73 (P = 0.006) Total events 261 391 Heterogeneity: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 51 391 Heterogeneity: Tau ² = 0.24, Ch ² = 0.11, df = 1 (P = 0.52); P = 0%. C C Experimental Control Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 31.1 Low dose (120mg) Dog 2013 5 50 13 50 3.7% 0.38 (0.15, 1.00] Lu 2017 28 54 31 42 11.5% 0.74 (0.59, 0.33] Ma 2016 2 55 12 55 1.3% 0.37 (0.38 (0.15, 1.00] Ma 2016 2 55 (2) 55 0.3% 0.38 (0.14, 1.03] Heterogeneity: Tau ² = 0.24, Ch ² = 26.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: Z = 3.26 (P = 0.001) 31.2 High dose (2300g) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 (0.45, 1.49] Huang 2017 18 100 28 100 8.1% 0.64 (0.43, 0.93] Zou 2013 67 210 81 210 13.0% 0.83 (0.64, 1.07] Subtotal (95% CI) 648 63 56.4% 0.77 (0.66, 0.91] Coal events 103 Heterogeneity: Tau ² = 0.00; Ch ² = 28.20, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: Z = 3.10 (P = 0.002) Total events 103 Heterogeneity: Tau ² = 0.00; Ch ² = 28.20, df = 12 (P = 0.004); l ² = 59% Total events 103 Heterogeneity: Tau ² = 0.00; Ch ² = 29.20, df = 12 (P = 0.004); l | | | | | | | | |
| $ \frac{2 hang X 2014}{2 0 u 2013} 4 4 50 0 6 2 100 8.9\% 0.26 [0.16, 0.41] 0.16 0.4 11 0.16 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 3.78] 0.00 0.26 1.78] 0.00 0.26 3.78] 0.00 0.26 1.78] 0.00 0.26 1.78] 0.00 0.26 1.78] 0.00 0.26 1.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.00 0.26 0.78] 0.01 0.1 0.1 0.1 0.0 0.01 0.1 0.0 0.01 0.01 0.01 0.01 0.01 0.00 0.$ | | | | | | | | |
| Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% C) 619 604 55.8% 0.62 [0.44, 0.87] Total events 112 195 Total events 213 195 Total events 261 391 Heterogeneity: Tau ² = 0.14; Ch ² = 13.006] Total (95% C) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect Z = 4.19 (P < 0.0001) Test for overall effect Z = 4.19 (P < 0.0001) Test for overall effect Z = 4.19 (P < 0.0001) Test for overall effect Z = 4.19 (P < 0.0001) Test for overall effect Z = 55 113 50 3.7% 0.38 (0.15, 1.00] Lu 2013 5 50 13 50 3.7% 0.38 (0.15, 1.00] Lu 2013 4 7 84 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 5 51 13 81 3.81 3.6% 0.38 (0.14, 1.03] Lu 2013 4 7 84 4 59 78 13.7% 0.74 (0.59, 0.93] Lu 2013 5 51 12 55 1.9% 0.17 (0.04, 0.71] Subtotal (95% C) 4224 406 43.6% 0.45 [0.27, 0.72] Total events 103 100 Heterogeneity: Tau ² = 0.24; Ch ² = 2.62, ff = 5 (P < 0.0001); I ² = 81% Test for overall effect: Z = 3.26 (P = 0.001) 3.12 High dose (2300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 12 05 33 50 10.6% 0.46 (0.38, 10.8] Qi 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 20 45 1.149 Hu 2015 14 53 20 43 100 8.1% 0.64 (0.03, 0.93] Zhang (F2014 21 50 33 50 10.6% 0.64 (0.38, 10.8] Qi 2013 67 7 10 8 100 28 100 8.1% 0.64 (0.38, 10.8] Qi 2013 67 210 81 1200 13 1.00 4 50 2.2% 0.077 [0.66, 0.91] Total events 158 201 Heterogeneity: Tau ² = 0.00; Ch ² = 2.26, 1df = 6 (P = 0.86); I ² = 0.% Test for overall effect Z = 3.261, df = 6 (P = 0.86); I ² = 0.% Test for overall effect Z = 3.11 (P = 0.002) Total events 261 391 Heterogeneity: Tau ² = 0.00; Ch ² = 2.261, df = 12 (P = 0.004); I ² = 59% | | | | | | | | |
| Subtolal (95% CI) 619 604 55.8% 0.62 [0.44, 0.87] Total events 112 195 Total events 112 195 Total events 112 195 Total events 112 195 Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for overall effect: Z = 4.19 (P < 0.0001) Test for subarous differences: Chi ^P = 0.41, df = 1 (P = 0.52). I ² = 0% C C C C C C C C C C C C C | | | | | | | | |
| Total events 112 195 Heterogeneity: Tau ² = 0.14; Chi ² = 19.90, df = 7 (P = 0.006); l ² = 65% Test for overall effect: 2 = 2.73 (P = 0.006) Total events 261 391 Heterogeneity: Tau ² = 0.7 (Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: 2 = 4.19 (P < 0.0001) Test for overall effect: 2 = 4.19 (P < 0.0001) Test for overall effect: 2 = 4.19 (P < 0.0001) Test for suboroup differences: Chi ² = 0.41, df = 1 (P = 0.52), P = 0%. C Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 3.11 Low dose (120mg) Dong 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Dong 2013 5 81 13 81 3.6% 0.38 [0.15, 1.00] Ma 2011 5 81 13 81 3.6% 0.38 [0.15, 1.00] Ma 2016 2 55 12 55 1.9% 0.74 [0.59, 0.93] Luz 2017 28 54 31 42 11.9% 0.70 [0.51, 0.96] Ma 2016 2 55 12 55 1.9% 0.17 [0.04, 0.71] Subtotal (95% CI) 4224 406 43.6% 0.45 [0.27, 0.72] Total events 103 190 Heterogeneity: Tau ² = 0.24; Chi ² = 26.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: 2 = 3.26 (P = 0.001) 3.12 High dose (230mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] 0 (2013 67 210 81 210 13.0% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 81 210 13.0% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 81 210 13.0% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 61 2.01 13.0% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 61 2.01 13.0% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 61 2.01 1.10% 0.83 (0.64, 1.03, 1.08] 0 (2013 67 210 61 2.01 1.10% 0.83 (0.64, 1.07] Total events 158 2010 Heterogeneity: Tau ² = 0.00; Chi ² = 2.50, df = 5 (P < 0.0001) Total events 261 33 50 10.6% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.07, Chi ² = 2.50, df = 12 (P = 0.004); l ² = 55% Total events 261 391 Heterogeneity: Tau ² = 0.07, Chi ² = 2.50, df = 12 (P = 0.004); l ² = 55% Total events 261 391 Heterogeneity: Tau ² = 0.07, Chi ² = 2.50, df = 12 (P = 0.004); l ² = 55% | | 4 | | 4 | | | | • |
| Total (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 ($P = 0.004$); P = 59% Test for overall effect: Z = 4.19 ($P < 0.0001$) Test for subarouo differences: Chi ² = 0.41. df = 1 ($P = 0.52$). P = 0% C C Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 3.1.1 Low dose (120mg) Dong 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.74 [0.59, 0.93] Lu 2013 47 84 59 78 13.7% 0.74 [0.59, 0.93] Lu 2013 2 5 51 2 55 1.9% 0.71 [0.04, 0.71] Aaa 2016 2 55 12 55 1.9% 0.71 [0.04, 0.71] Zhang X2014 16 100 62 100 8.9% 0.26 [0.16, 0.41] Subtotal (95% CI) 422 4 45 30 45 1.1.4% 0.89 [0.57, 1.13] Total events 103 190 Heterogeneity: Tau ² 0.02; Chi ² = 25.5; df = 5 ($P < 0.0001$); l ² = 81% Test for overall effect: Z = 3.26 ($P = 0.001$) 3.1.2 High dose ($\geq 300mg$) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Q12013 27 41 53 31 7 53 7.0% 0.82 [0.45, 1.49] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Q12013 47 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 35.4% 0.77 [0.66, 0.91] Total events 158 201 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 6 ($P = 0.86$); l ² = 0% Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 158 201 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 6 ($P = 0.86$); l ² = 0% Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 6 ($P = 0.86$); l ² = 0% Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 6 ($P = 0.86$); l ² = 0% Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 16 ($P = 0.86$); l ² = 0% Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.51, df = 16 ($P = 0.66$); l ² = 0% Test for overall effect: Z = 3 | Total events Heterogeneity: Tau ² = | 0.14; Chi ² | | df = 7 (F | 9 = 0.00 | 06); l² = 65 | | |
| Total events 281 391 Heterogeneity: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for subaroup differences: Chi ² = 0.41. df = 1 (P = 0.52), P = 0% C C C C C C C Experimental Control Experimental Control Risk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Andom, 95% CI Andom, 95% CI Andom, 95% CI M-H, Random, 95% C | | Z = 2.73 (I | | 5) | 1039 | 100.0% | 0 64 [0 52 0 79] | • |
| Heterogeneity: Tau ² = 0.07; Ch ² = 29.20, df = 12 (P = 0.004); P = 59% Test for overall effect: Z = 4.19 (P < 0.0001) Test for subaroup differences: Ch ² = 0.41. df = 1 (P = 0.52). P = 0% C Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 3.11 Low dose (120mg) Dong 2013 5 50 13 50 3.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.15, 1.00] Lu 2013 47 84 59 78 13.7% 0.38 [0.16, 0.41] Subtotal (95% CI) 424 406 43.6% 0.45 [0.27, 0.72] Total events 103 190 Heterogeneity: Tau ² = 0.24; Chi ² = 26.25, df = 5 (P < 0.0001); I ² = 81% Test for overall effect: Z = 3.26 (P = 0.001) 3.1.2 High dose (2300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 10.8] Qi 2013 267 210 81 210 13.0% 0.83 [0.64, 1.07] Subtotal (95% CI) 648 6 633 50.4% 0.77 [0.66, 0.91] Total events 158 201 Huang 2017 18 100 28 100 8.1% 0.64 [0.43, 0.93] Qi 2013 267 210 81 210 13.0% 0.68 [0.64, 1.07] SizUl3 24 45 30 45 11.4% 0.80 [0.57, 1.13] Qi 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Qi 2013 26 210 81 210 13.0% 0.64 [0.43, 0.93] Qi 2013 26 210 81 210 13.0% 0.64 [0.43, 0.93] Qi 2013 26 210 81 210 13.0% 0.64 [0.43, 0.93] Qi 2013 26 210 81 210 13.0% 0.64 [0.43, 0.93] Qi 2013 26 210 81 210 13.0% 0.64 [0.43, 0.93] Qi 2013 26 210 81 210 13.0% 0.64 [0.52, 0.79] Total events 158 201 Heterogeneity: Tau ² = 0.07, Chi ² = 29.20, df = 12 (P = 0.004); I ² = 59% Total events 261 391 Heterogeneity: Tau ² = 0.27, Chi ² = 29.20, df = 12 (P = 0.004); I ² = 59% | | 261 | | 391 | | | | |
| The provided effect $Z = 4, 19 (P < 0.0001)$ Test for subarous differences: Chi ^P = 0.41. df = 1 (P = 0.52). P = 0%. C Experimental Control Risk Ratio M-H, Random, 95% CI M-H, | Heterogeneity: Tau ² = | 0.07; Chi ² | | df = 12 (| P = 0.0 | 004); l ² = 5 | 9% | |
| Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI 3.1.1 Low dose (120mg) | | | | | P = 0.5 | 62). I² = 0% | | |
| Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI 3.1.1 Low dose (120mg) | С | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | Events | | | | Weight M | | |
| Lu 2013 47 84 59 78 13.7% 0.74 $[0.59, 0.33]$ Luo 2017 28 54 31 42 11.9% 0.70 $[0.51, 0.96]$ Ma 2011 5 81 13 81 3.6% 0.38 $[0.14, 1.03]$ Ma 2016 2 55 12 55 1.9% 0.17 $[0.04, 0.71]$ Subtotal (95% CI) 424 406 43.6% 0.45 $[0.27, 0.72]$ Total events 158 201 Heterogeneity: Tau ² = 0.24; Chi ² = 2.625, df = 5 ($P < 0.0001$); l ² = 81% Test for overall effect: Z = 3.26 ($P = 0.001$) 3.1.2 High dose (\geq 300mg) Chen 2013 10 140 8 125 4.1% 1.12 $[0.45, 2.74]$ Huang 2017 18 100 28 100 8.1% 0.64 $[0.38, 1.68]$ Qi 2013 67 210 81 210 13.0% 0.83 $[0.64, 1.07]$ Si 2013 24 45 30 45 11.4% 0.80 $[0.57, 1.13]$ Zhang GF2014 21 50 33 50 10.6% 0.64 $[0.43, 0.93]$ Course 158 201 Total events 158 201 Total events 261 391 Total events 261 391 Total events 261 291 Total events 261 291 | | 5 | 50 | 13 | 50 | 3.7% | 0.38 [0.15, 1.00] | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Lu 2013 | | 84 | 59 | 78 | 13.7% | 0.74 [0.59, 0.93] | |
| Ma 2016 2 55 1.2 55 1.9% 0.17 [0.04, 0.71] Zhang X2014 16 100 62 100 8.9% 0.26 [0.16, 0.41] Subtotal (95% CI) 424 406 43.6% 0.45 [0.27, 0.72] Total events 103 190 Heterogeneity: Tau ² = 0.24; Ch ² = 26.25, df = 5 ($P < 0.0001$); $I2 = 81\%$ Test for overall effect: Z = 3.26 ($P = 0.001$) 3.1.2 High dose (≥300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Qi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang GF2014 21 50 33 50 10.6% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.2% 1.00 [0.56, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 ($P = 0.86$); $I2 = 0\%$ Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 261 391 Heterogeneity: Tau ² = 0.00; Chi ² = 2.9.20, df = 12 ($P = 0.004$); $I2 = 59\%$ | | | | | | | | |
| Subtotal (95% CI) 424 406 43.6% 0.45 [0.27, 0.72] Total events 103 190 Heterogeneity: Tau ² = 0.24; Chi ² = 26.25, df = 5 (P < 0.0001); l ² = 81% Test for overall effect: Z = 3.26 (P = 0.001) 3.1.2 High dose (≥300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Qi 2013 67 210 8.1 210 13.0% 0.83 [0.64, 1.07] Si 2013 24 45 30 45 1.4% 0.80 [0.57, 1.13] Zhang GF2014 21 50 33 50 1.06% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.5 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] • Total events 158 201 1039 100.0% 0.64 [0.52, 0.79] • Total events 261 391 100.0% 0.64 [0.52, 0.79] • • • < | Ma 2016 | 2 | 55 | 12 | 55 | 1.9% | 0.17 [0.04, 0.71] | |
| Total events 103 190 Heterogeneity: Tau ² = 0.24; Chi ² = 26.25, df = 5 ($P < 0.0001$); $I^2 = 81\%$ Test for overall effect: Z = 3.26 ($P = 0.001$) 3.1.2 High dose (\geq 300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.49] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Qi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Zhang GF2014 21 50 33 50 10.6% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Total events 158 Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 ($P = 086$); $I^2 = 0\%$ Test for overall effect: Z = 3.11 ($P = 0.002$) Total (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 Heterogeneity: Tau ² = 20.7; Chi ² = 29.20, df = 12 ($P = 0.004$); $I^2 = 59\%$ | | 16 | | 62 | | | | |
| Heterogeneity: Tau ² = 0.24; Chi ² = 26.25, df = 5 ($P < 0.0001$); I^2 = 81% Test for overall effect: Z = 3.26 ($P = 0.001$) 3.1.2 High dose (\geq 300mg) Chen 2013 10 140 8 125 4.1% 1.12 [0.45, 2.74] Hu 2015 14 53 17 53 7.0% 0.82 [0.45, 1.49] Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Qi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang GF2014 21 50 33 50 10.6% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% Cl) 648 633 56.4% 0.77 [0.66, 0.91] Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 ($P = 0.86$); $I^2 = 0\%$ Test for overall effect: Z = 3.11 ($P = 0.002$) Total events 158 201 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 ($P = 0.004$); $I^2 = 59\%$ | Total events | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | (P < 0. | 0001); l ² = | = 81% | |
| Hu 2015 14 53 17 53 7.0% 0.82 $[0.45, 1.49]$ Huang 2017 18 100 28 100 8.1% 0.64 $[0.38, 1.08]$ Qi 2013 67 210 81 210 13.0% 0.83 $[0.64, 1.07]$ Si 2013 24 45 30 45 11.4% 0.80 $[0.57, 1.13]$ Zhang GF2014 21 50 33 50 10.6% 0.64 $[0.43, 0.93]$ Zou 2013 4 50 4 50 2.2% 1.00 $[0.26, 3.78]$ Subtotal (95% CI) 648 633 56.4% 0.77 $[0.66, 0.91]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 (P = 0.86); l ² = 0% Test for overall effect: Z = 3.11 (P = 0.002) Total events 158 201 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% | 3.1.2 High dose (≥3 | 00mg) | | | | | | |
| Huang 2017 18 100 28 100 8.1% 0.64 [0.38, 1.08] Qi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang GF2014 21 50 33 50 10.6% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Total events 158 201 1000c Chi 4[0.52, 0.79] 4 Total events 261 391 100.0% 0.64 [0.52, 0.79] 4 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% $0.1 \ 0.2$ 0.5 2 5 1 | | | | | | | | |
| Qi 2013 67 210 81 210 13.0% 0.83 [0.64, 1.07] Si 2013 24 45 30 45 11.4% 0.80 [0.57, 1.13] Zhang GF2014 21 50 33 50 10.6% 0.64 [0.43, 0.93] Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 (P = 0.86); l ² = 0% Test for overall effect: Z = 3.11 (P = 0.002) Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% | | | | | | | | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | Qi 2013 | 67 | 210 | 81 | 210 | 13.0% | 0.83 [0.64, 1.07] | |
| Zou 2013 4 50 4 50 2.2% 1.00 [0.26, 3.78] Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Total events 158 201 Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 (P = 0.86); l ² = 0% Test for overall effect: Z = 3.11 (P = 0.002) Total events 261 391 Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% 0.1 0.2 0.5 1 2 5 1 | | | | | | | | |
| Subtotal (95% CI) 648 633 56.4% 0.77 [0.66, 0.91] Total events 158 201 Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 (P = 0.86); l ² = 0% Test for overall effect: Z = 3.11 (P = 0.002) Total (95% CI) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% | Zou 2013 | | | | 50 | 2.2% | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 2.61, df = 6 (P = 0.86); l ² = 0% Test for overall effect: Z = 3.11 (P = 0.002) Total (95% Cl) 1072 1039 100.0% 0.64 [0.52, 0.79] Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); l ² = 59% | Subtotal (95% CI) | | | 201 | | | | • |
| Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); I ² = 59% | Heterogeneity: Tau ² = | 0.00; Chi | | df = 6 (| P = 0.8 | 6); I ² = 0% | 5 | |
| Total events 261 391 Heterogeneity: Tau ² = 0.07; Chi ² = 29.20, df = 12 (P = 0.004); I ² = 59% | | | | | 039 | 100.0% | 0.64 [0.52, 0.79] | • |
| | Total events | | | 391 | | | | - |
| Test for overall effect: $Z = 4.19 (P < 0.0001)$ | | | 2 = 29.20 | | 2 (P = 0) | 0.004); I ² = | = 59% | 0.1 0.2 0.5 1 2 5 10 |

with the standard triple therapy; (B). Subgroup analysis about the treatment duration; (C). Subgroup analysis about the dose of berberine.



inflammation are considered to be the main causes of peptic ulcers (Miftahussurur, 2015). A meta-analysis reported that PUD is more common in H. pylori-positive patients, and H. pylori eradication therapy can reduce PUD incidence (Tang et al., 2012). In 1989, berberine was found to inhibit the formation of an ethanol-induced ulcer, aspirin-induced ulcer, and H. pyloriinfected ulcer (Uchiyama and Kamikawa, 1989). Recent studies have reported that berberine can protect the gastric mucosa from being damaged by ethanol and attenuate intestinal mucosal barrier dysfunction in type 2 diabetic rats (Pan et al., 2005; Gong et al., 2017). Based on these findings, we further explored the efficiency of berberine-containing quadruple therapy for peptic ulcers. In these included studies, 10 studies reported the healing condition of ulcers. The outcomes of peptic ulcer healing varied. Four of the 10 included articles judged the healing of ulcers where ulcer lesions were significantly improved or ulcers were completely healed (red or white scars formed) under gastroscopy. The remaining six articles judged healing as scar formation or ulcer lesions shrink below 50%. Our review showed that Hp-infected ulcer lesions were significantly improved by adding berberine to the standard triple therapy compared with standard triple therapy. This phenomenon illustrated that berberine can help increase the eradication rate of *H. pylori*.

The clinical symptoms of *H. pylori* infection are sometimes not obvious, sometimes acid reflux, heartburn, and stomachache. This is mainly due to *H. pylori*-induced secretion of gastrin. In the included studies, five articles reported improvement in clinical symptoms. Next, we investigated whether berberinecontaining quadruple therapy can improve clinical symptoms. The results showed that the addition of berberine in standard triple therapy could significantly improve clinical symptoms and reduce the frequency compared with the standard triple therapy. The possible reason was that berberine protects the gastrointestinal mucosa and kills *H. pylori* to reduce gastrin release.

In addition, the berberine-containing quadruple therapy in our review appeared to be safe. The adverse reactions were commonly gastrointestinal discomfort, including nausea, vomiting, bloating, diarrhea, anorexia, and few mentioned the abnormal taste and liver function. As shown in the analysis, the adverse event rates were 24.6% (264/1072) and 37.6% (391/ 1039) in the experimental group and the control group, respectively. However, there was greater heterogeneity in the included studies. The results of the meta-regression showed that there was no difference regarding the publication year, the method, the PPI type, the total number of participants, the dose of berberine, and the time of treatment duration. Although the time of treatment duration was different in different studies, varying from 7 days to 10 days to 14 days, Chen's study performed a sequential experiment, and the results showed that the H. pylori eradication rate and clinical symptom remission rate of 7 days were lowest, and the adverse reactions were fewest (Chen et al., 2013). The H. pylori eradication rate and clinical symptom remission rate of 14 days were the highest, and the incidence of adverse reactions increased accordingly. The 10 day treatment had a

good *H. pylori* eradication rate and clinical symptom relief rate, and the incidence of adverse reactions was relatively low. There was no significant difference between the 10 days and 14 days in the *H. pylori* eradication rate, so the 10 day treatment course was the best in terms of comprehensive efficacy and safety (Chen et al., 2013). However, in the fifth national consensus report on the treatment of *H. pylori* infection (in China, 2016), treatment for 14 days is recommended (Liu et al., 2018).

Limitations

There are also some limitations to our study. First, all trials included were conducted in mainland China, and it is still questionable whether the results are applicable in other areas due to genetics and region differences. Helicobacter pylori eradication should be assessed on the 28th day after the end of treatment with 13^C/14^C-UBT and/or RUT. Ten out of 13 studies confirmed the test time, but three studies did not mention the detection time. Therefore, the literature included in this study is not rigorous enough. These results require further study. Third, in the included studies, the dosage of berberine and treatment duration were not completely consistent. Finally, there are some limitations in the included literature and methodology in this systematic evaluation. The Jadad score of the included studies is generally high, and Egger's tests illustrated that there was no publication bias in these studies except for the Hp eradication rate. Bias may result from poor design of clinical research such as randomized, controlled, and blind methods and small sample sizes. Most of the included studies were too simple in the description of the random method, and the courses of treatment in these studies were inconsistent. The baseline comparability and loss of visit/withdrawal were not fully reported, and there were differences in the dosage and measurement methods, all of which could have an impact on the results and result in low test efficacy. Therefore, the effect of adding berberine to the standard triple therapy on H. pylori should be carefully interpreted based on substantial methodological and clinical research design.

REFERENCES

- Adachi, K., Notsu, T., Mishiro, T., Yoshikawa, H., and Kinoshita, Y. (2018). Influence of helicobacter pylori infection on periodontitis. J. Gastroenterol. Hepatol. 34 (1), 120–123. doi: 10.1111/jgh.14358
- Chang, C. H., Huang, W. Y., Lai, C. H., Hsu, Y. M., Yao, Y. H., Chen, T. Y., et al. (2011). Development of novel nanoparticles shelled with heparin for berberine delivery to treat helicobacter pylori. *Acta Biomater*. 7 (2), 593–603. doi: 10.1016/j.actbio.2010.08.028
- Chen, J., Zhang, Q. X., and Zhang, Q. (2013). Therapeutic effect of berberine combined with triple regimen on different courses of treatment of Helicobacter pylori. J. Yangtze Univ. (Nat. Sci. Edit). 10 (36), 1–5. (In Chinese).
- Chen, Z. S., Chen, Y. H., Lv, N. H., and Zhou, L. Y. (2019). Expert consensus on the eradication of helicobacter pylori eradication and prevention and control of gastric cancer in China. *Chin. J. Digestion* 5 (39), 310–316. (In Chinese).
- Debraekeleer, A. (2018). Future perspective for potential helicobacter pylori eradication therapies. *Future Microbiol.* 13, 671–687. doi: 10.2217/fmb-2017-0115
- Dong, J. W., and Dai., Y. (2013). Therapeutic effect of berberine combined with triple therapy on eradication of helicobacter pylori infection. *Clin. Ration. Drug Use* 6 (24), 56–57. (In Chinese).

Conclusions

The analysis showed that the addition of berberine in standard triple therapy could improve the *H. pylori* eradication rate and clinical symptom remission rate, accelerate ulcer healing and reduce adverse events compared to the standard triple therapy, which provided a new method for the eradication of *H. pylori* and is very beneficial to clinical work in China.

AUTHOR CONTRIBUTIONS

PY designed the study. QH and ZP conducted the experiments and wrote the manuscript. LL, XZ, LX and JG revised the manuscript. All authors approved the final version to be published.

FUNDING

This article was supported by the National Natural Science Foundation of China (No.81673757).

ACKNOWLEDGMENTS

We thank all authors of the references for performing RCTs of berberine-containing quadruple therapy on *Helicobacter pylori* eradication. We are also thankful for the generous help provided by Lingli Li and Jing Gong.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019. 01694/full#supplementary-material

- Eusebi, L. H., and Zagari, R. M. (2014). Epidemiology of helicobacter pylori infection. *Helicobacter* 19 (Suppl 1), 1–5. doi: 10.1111/hel.12165
- Gong, J., Hu, M., Huang, Z. Y., Fang, K., Wang, D. K., Chen, Q. J., et al. (2017). Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats. *Front. Pharmacol.* 8, 42. doi: 10.3389/fphar.2017.00042
- Graham, D. Y., and Lee, S. Y. (2015). How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. *Gastroenterol. Clin. North Am.* 44 (3), 537–563. doi: 10.1016/j.gtc.2015.05.003
- Hu, W. B. (2015). Evaluation of the efficacy of berberine combined with "triple" therapy in patients with helicobacter pylori infection. *Anti-Infect Pharm.* 12 (04), 616–618. (In Chinese).
- Huang, Y. Q., Huang, G. R., Wu, M. H., Tang, H. Y., Huang, Z. S., Zhou, X. H., et al. (2015). Inhibitory effects of emodin, baicalin, schizandrin and berberine on hefA gene: treatment of Helicobacter pylori-induced multidrug resistance. *World J. Gastroenterol.* 21 (14), 4225–4231. doi: 10.3748/wjg.v21.i14.4225
- Huang, L., Chen, N., and Yu, Z. (2017). Clinical efficacy of berberine combined with triple therapy in the treatment of helicobacter pylori-positive peptic ulcer. *Mod. Pract. Med.* 29 (05), 591–593. (In Chinese).
- Kahramanoğlu Aksoy, E., Pirinçci Sapmaz, F., Göktaş, Z., Uzman, M., and Nazlıgül, Y. (2017). Comparison of helicobacter pylori eradication rates of 2week levofloxacin-containing triple therapy, levofloxacin-containing bismuth

quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen. *Med. Princ. Pract.* 26, 523–529. doi: 10.1159/000484930

- Lee, M., Baek, H., Park, J. S., Kim, S., Kyung, C., Bail, S. J., et al. (2018). Current helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: a cross-sectional study. *PloS One* 13 (3), e0193646. doi: 10.1371/journal.pone.0193646
- Li, C., Xie, J., Chen, X., Mo, Z. Z., Wu, W., Liang, Y., et al. (2016). Comparison of helicobacter pylori urease inhibition by rhizoma coptidis, cortex phellodendri and berberine: mechanisms of interaction with the sulfhydryl group. *Planta Med.* 82 (4), 305–311. doi: 10.1055/s-0035-1558229
- Li, B. (2011). Clinical study of berberine hydrochloride in the treatment of peptic ulcer. *China Mod. Med.* 18 (24), 62–63. (In Chinese).
- Lin, Y. H., Lin, J. H., Chou, S. C., Chang, S. J., Chung, C. C., Chen, Y. S., et al. (2015). Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: *in vitro* and *in vivo* study. *Nanomed* (Lond) 10 (1), 57–71. doi: 10.2217/nnm.14.76
- Liu, W. Z., Xie, Y., Cheng, H., Lv, N. H., Hu, F. L., Zhang, W. D., et al. (2012). The fourth national consensus report on the treatment of Helicobacter pylori infection. *Chin. J. Gastroenterol.* 17 (10), 618–625. (In Chinese).
- Liu, W. Z., Xie, Y., Lu, H., Cheng, H., Zeng, Z. R., Zhou, L. Y., et al. (2018). Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. *Helicobacter* 23 (2), e12475. doi: 10.1111/hel.12475
- Lu, Z. B., Wang, M. M., and Chen, L. M. (2013). Clinical study of berberine combined with triple therapy for eradication of Helicobacter pylori infection. *Chin. J. Mod. Drug Appl.* 7 (04), 84–85. (In Chinese).
- Lu, Y. B. (2018). Clinical application analysis of berberine hydrochloride in treating helicobacter pylori infected gastric ulcer. J. Clin. Med. 5 (100), 41–42. (In Chinese).
- Luo, Q., Mao, Q., Hong, X., and Zhao, Q. H. (2017). Therapeutic effect of berberine combined with antibacterial triple therapy on type 2 diabetes mellitus complicated with Helicobacter pylori infection and peptic ulcer. *Internal Med.* 12 (03), 384–386. (In Chinese).
- Ma, T. H., Wu, S. N., Gao, C. C., and Xie, R. (2011). Treatment of 54 cases of Helicobacter pylori infection with berberine combined with triple therapy. *Chin. J. Integr. Trad. West Med. Dig.* 19 (03), 190–191. (In Chinese).
- Ma, L. J. (2016). Clinical analysis of helicobacter pylori infection in patients treated with berberine combined with triple therapy. World Latest Med. Inf. (Electronic Version). 16 (96), 118–119. (In Chinese).
- Miftahussurur, M. (2015). Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease. *Expert Rev. Gastroenterol. Hepatol.* 9 (12), 1535–1547. doi: 10.1586/17474124.2015.1095089
- Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* 4, 1. doi: 10.1186/2046-4053-4-1
- Pan, L. R., Tang, Q., Fu, Q., Hu, B. R., Xiang, J. Z., and Qian, J. Q. (2005). Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol. Sin. 26 (11), 1334–1338. doi: 10.1111/j.1745-7254.2005.00186.x
- Papastergiou, V., and Georgopoulos, S. D. (2014). Treatment of helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J. Gastroenterol. 20 (29), 9898–9911. doi: 10.3748/wjg.v20.i29.9898
- Qi, J. H., and Xiao, P. Y. (2013). Clinical observation of berberine combined with triple therapy in the treatment of helicobacter pylori infection. *Natl. Med. Front. China* 8 (22), 23–24. (In Chinese).
- Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., and Tacconelli, E. (2018). Prevalence of antibiotic resistance in helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. *Gastroenterology* 155 (5), 1372–1382.e17. doi: 10.1053/j.gastro.2018.07.007

- Si, J. S., and Hu, Y. L. (2013). Clinical aurative effect observation of berberine combined with triple therapy in eradicating helicobacter pylori infection. *China J. Mod. Drug May* 7 (15), 10–11. (In Chinese).
- Tan, L., Li, C., Chen, H. B., Mo, Z. Z., Zhou, J. T., Liu, Y. H., et al. (2017). Epiberberine, a natural protoberberine alkaloid, inhibits urease of Helicobacter pylori and jack bean: susceptibility and mechanism. *Eur. J. Pharm. Sci.* 110, 77– 86. doi: 10.1016/j.ejps.2017.02.004
- Tang, C. L., Ye, F., Liu, W., Pan, X. L., Qian, J., and Zhang, G. X. (2012). Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. *Helicobacter* 17 (4), 286–296. doi: 10.1111/j.1523-5378.2012. 00942.x
- Uchiyama, T., and Kamikawa, H. (1989). [Anti-ulcer effect of extract from phellodendri cortex]. Yakugaku zasshi 109 (9), 672–676. doi: 10.1248/ yakushi1947.109.9_672
- Wu, X., Li, X., and Dang, Z. (2018). Berberine demonstrates anti-inflammatory properties in helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. *J. Cell. Biochem.* 119 (7), 5373–5381. doi: 10.1002/jcb.26681
- Xie, C., and Lv, N. H. (2017). Current situation of helicobacter pylori infection in china and advantages and disadvantages of eradication therapy. *Chin. J. Int. Med.* 56 (5), 327–330. (In Chinese).
- Xu, C., Yan, M., Sun, Y., Joo, J. S., Wan, X. Y., Yu, C. H., et al. (2014). Prevalence of Helicobacter pylori infection and its relation with body mass index in a Chinese population. *Helicobacter* 19 (6), 437–442. doi: 10.1111/hel.12153
- Yang, J. C., and Lu, C. W. (2014). Treatment of Helicobacter pylori infection: current status and future concepts. World J. Gastroenterol. 20 (18), 5283– 5293. doi: 10.3748/wjg.v20.i18.5283
- Yong, W. C., and Upala, S. (2018). Association between Psoriasis and Infection: A Systematic Review and Meta-analysis. *Indian J. Dermatol.* 63 (3), 193–200.
- Zhang, D., Ke, L., Ni, Z., Chen, Y., Zhang, L. H., Zhu, S. H., et al. (2017). Berberine containing quadruple therapy for initial Helicobacter pylori eradication: an open-label randomized phase IV trial. *Medicine* 96 (32), e7697. doi: 10.1097/ MD.000000000007697
- Zhang, M. F. (1992). Anti-diarrhea effect and mechanism of Berberine. Northwest Pharm. J. 7 (01), 36–38. (In Chinese).
- Zhang, G. F. (2014). Therapeutic effect of Berberine combined with triple therapy on eradication of Helicobacter pylori infection. *Chin. J. Tranma Disability Med.* 22 (10), 171–172. (In Chinese).
- Zhang, X. X. (2014). Clinical effect of Berberine combined with triple therapy for helicobacter pylori infection. *Clin. Med. Eng.* 21 (03), 323–324. (In Chinese).
- Zhou, H. L., Xie, C. D., Wang, Q. Y., Zhang, Y. J., and Xia, H. B. (2013). Clinical observation of adjuvant therapy of Berberine on type 2 diabetes plus peptic ulcer with HP infection 13, 09, 1745–1747. (In Chinese).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hu, Peng, Li, Zou, Xu, Gong and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.